fashion -WSS

fashion

author：focus 2025-08-12 08:28:04 - browse：4529

Lung cancer under microscope — coverage from STAT — Lung cancer Adobe

CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the design of a key clinical trial.

Delfi also announced that the Merck Global Health Innovation Fund, the VC arm of the drug giant, has made an investment of an undisclosed amount in the company.

Unlike Grail, a unit of Illumina, or Exact Sciences, which seeks to develop a blood test that can be used to screen for multiple types of cancer, Delfi is focusing on a single disease — lung cancer — in which the utility of screening with existing technology is not in dispute. Using low-dose CT scans to detect lung cancer is considered an established technology for people at higher risk of lung cancer. However, far too few people get screened.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Hospitals are piloting generative AI tools as regulators play catch

WSS

A new drug could help frostbite victims avoid its ravages

Weight loss drugs aren’t covered by Obamacare. That may change

AstraZeneca to buy developer of next

New study raises questions about niacin and heart health

AstraZeneca to buy developer of next

A new drug could help frostbite victims avoid its ravages

Wikipedia

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Virtual Event: March of the Biosimilars

State Dept. review finds Biden bears some blame for Afghanistan failures

Researchers tackle phage therapy hurdles for wider adoption

Moonlake's readout produced a cash windfall. Risks remain

Health AI adoption puts security, privacy startups on investors' radar

Walensky prepares to leave CDC — and Congress — behind

Surprise medical billing ban raises prices elsewhere

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Surprise medical billing ban raises prices elsewhere

leisure time

Flagship Pioneering startup Sonata Therapeutics lays off 21

Medicare Advantage enrollment hits roughly 33.4 million

A new drug could help frostbite victims avoid its ravages

Stop the failed accountable care organization experiment

Medicare Advantage enrollment hits roughly 33.4 million

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

focus

hotspot

explore

hotspot